Arthneeti
All Q2 FY27 results →
SP

Sudeep Pharma Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Sudeep Pharma Q2 Results 2026 (FY27): Revenue ₹196.7 Cr, PAT ₹51.8 Cr

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹1,119
Market cap₹12.6K Cr
P/E69.2
Updated28 Oct 2026
Read4 min read

Sudeep Pharma Ltd Q2 FY27 key numbers

Revenue
Q2 FY27 Revenue from Operations: Rs 196.7 crore.

As stated in Sudeep Pharma Ltd's Q2 FY27 investor presentation · published 28 Oct 2026. Reported figures, not investment advice.

Based on Sudeep Pharma Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 Revenue from Operations: Rs 196.7 crore - Q2 FY26 Revenue: Rs 162.7 crore - Year-on-Year (YoY) Growth: 21% increase - H1 FY27 Revenue: Rs 355.0 crore (up 23% YoY from Rs 287.6 crore in H1 FY26) - Segment Revenue Split (Q2 FY27): - Pharma & Food Nutrition: 72% of revenue - Specialty Ingredients: 28% of revenue - Geographical Split (Q2 FY27): - Exports: 65% - Domestic: 35% - Outlook: - FDA approval for Nandesari facility received; commercial supplies expected H2 FY27, potentially boosting revenue. Q2FY27 EBITDA: Rs 73.2 crore, up 32% YoY (Q2FY26 EBITDA: Rs 55.5 crore) - Q2FY27 EBITDA Margin: 37.2%, improved by approximately 70 basis points YoY (Q2FY26: 34.1%) - Q2FY27 Profit After Tax (PAT)

From Sudeep Pharma Ltd's Q2 FY27 earnings-call transcript · updated 28 Oct 2026.

Revenue & Sales Performance

  • Q2 FY27 Revenue from Operations: Rs 196.7 crore
  • Q2 FY26 Revenue: Rs 162.7 crore
  • Year-on-Year (YoY) Growth: 21% increase
  • H1 FY27 Revenue: Rs 355.0 crore (up 23% YoY from Rs 287.6 crore in H1 FY26)
  • Segment Revenue Split (Q2 FY27):
  • Pharma & Food Nutrition: 72% of revenue
  • Specialty Ingredients: 28% of revenue
  • Geographical Split (Q2 FY27):
  • Exports: 65%
  • Domestic: 35%
  • Outlook:
  • FDA approval for Nandesari facility received; commercial supplies expected H2 FY27, potentially boosting revenue.

2 more points from Sudeep Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

  • Q2FY27 EBITDA: Rs 73.2 crore, up 32% YoY (Q2FY26 EBITDA: Rs 55.5 crore)
  • Q2FY27 EBITDA Margin: 37.2%, improved by approximately 70 basis points YoY (Q2FY26: 34.1%)
  • Q2FY27 Profit After Tax (PAT): Rs 51.8 crore, up 11% YoY (Q2FY26 PAT: Rs 46.7 crore)

2 more points from Sudeep Pharma Ltd's call on margins

Create a free account to keep reading this call

Capital Expenditure Plans

  • Dahej Battery Materials Plant
  • Project cost: approx. Rs 300 crore
  • Product: Battery Grade Iron Phosphate for EV and Energy Storage
  • Land Area: 80,980 Sq. Mt.
  • Status: Construction progressing well, on track for completion by March 2027
  • Financing: Internal accruals + debt
  • New Pharma, Food & Nutrition Greenfield Expansion at Nandesari, Gujarat
  • Capacity: 51,200 MT annually
  • Total Capex: ~Rs 168 crore
  • Focused on pharmaceutical excipients, actives, and food & nutrition minerals
  • FDA approval received; internal validation complete; customer validation in progress
  • Financing: Internal accruals
  • Battery-grade Iron Phosphate Capacity Expansion
  • Target capacity: 105,000 MT (Phase 1: 25,000 MT)
  • Estimated project completion by March 2027
  • Additional 100,000 MT capacity under evaluation
  • Vitamin & Mineral Blends Business Acquisition

2 more points from Sudeep Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sudeep Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Sudeep Pharma Ltd said on order book & pipeline — free account, 30 seconds.

Sudeep Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹197 Cr, net profit ₹52 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Sudeep Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Jagsonpal Pharmaceuticals Ltd (Q2 FY27)

    Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY . Key investor presentation takeaways from Jagsonpal Pharmaceuticals Ltd's Q2 FY27 investor presentation — and

  • Zota Health Care Ltd (Q2 FY27)

    Revenue from Operations for Q2FY27 is ₹19,933.14 lakhs, up 54.58% YoY from ₹12,894.82 lakhs in Q2FY26. Key investor presentation takeaways from Zota Health Care

  • FDC (Q2 FY27)

    47,303 lakhs in Q2 September 2025 (approximately 20.9% YoY growth). Key results statement takeaways from FDC Ltd's Q2 FY27 results statement — and how it ranks

  • Indoco Remedies Ltd (Q2 FY27)

    Consolidated revenues for Q2 FY 2026-27 are ₹5,069 million, up 7.4% year-on-year (YoY) from ₹4,718 million in the same quarter last year. Key results statement

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sudeep Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sudeep Pharma Ltd Q2 FY27 results?

Q2 FY27 Revenue from Operations: Rs 196.7 crore - Q2 FY26 Revenue: Rs 162.7 crore - Year-on-Year (YoY) Growth: 21% increase - H1 FY27 Revenue: Rs 355.0 crore (up 23% YoY from Rs 287.6 crore in H1 FY26) - Segment Revenue Split (Q2 FY27): - Pharma & Food Nutrition: 72% of revenue - Specialty Ingredients: 28% of revenue - Geographical Split (Q2 FY27): - Exports: 65% - Domestic: 35% - Outlook: - FDA approval for Nandesari facility received; commercial supplies expected H2 FY27, potentially boosting revenue. Q2FY27 EBITDA: Rs 73.2 crore, up 32% YoY (Q2FY26 EBITDA: Rs 55.5 crore) - Q2FY27 EBITDA Margin: 37.2%, improved by approximately 70 basis points YoY (Q2FY26: 34.1%) - Q2FY27 Profit After Tax (PAT)

What is Sudeep Pharma Ltd share price analysis?

Sudeep Pharma Ltd currently shows a neutral. The stock trades at a P/E of 69.2 with a market cap of ₹12,635 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sudeep Pharma Ltd planning capital expenditure?

Dahej Battery Materials Plant - Project cost: approx.

Keep Sudeep Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.